Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 + Ibrutinib in Relapsed/Refractory DLBCL
NCT02780830Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of vistusertib in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events at 9 months, Overall Response Rate at 5 years and 1 more. Planned start Jun 2016; status: withdrawn.
02
Drugs
vistusertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02780830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780830.